Biocryst Pharmaceuticals (BCRX) Share-based Compensation Growth (1y) (2011 - 2026)
Powered by 
Analysis
Biocryst Pharmaceuticals (BCRX) Share-based Compensation Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.56 Bn | 197.57 Bn | 7.24 Bn | 19.90% |
| 2 | Gilead Sciences | 181.34 Bn | 178.16 Bn | 6.22 Bn | 2.67% |
| 3 | Vertex Pharmaceuticals | 132.22 Bn | 124.37 Bn | 2.84 Bn | 71.86% |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn | -3.46% |
| 5 | Argenx Se | 61.55 Bn | 56.37 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.32 Bn | 49.19 Bn | 52.00 Mn | -7.69% |
| 7 | Alnylam Pharmaceuticals | 34.32 Bn | 31.01 Bn | 992.69 Mn | -22.43% |
| 8 | Biogen | 31.24 Bn | 29.95 Bn | 1.96 Bn | 3.34% |
| 9 | Roivant Sciences | 30.17 Bn | 30.17 Bn | 1.16 Mn | - |
| 10 | Biocryst Pharmaceuticals | 2.31 Bn | 1.95 Bn | 214.41 Mn | -31.04% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -31.04% |
| Mar 31, 2026 | -25.00% |
| Dec 31, 2025 | 11.50% |
| Sep 30, 2025 | 7.84% |
| Jun 30, 2025 | 61.72% |
| Mar 31, 2025 | 56.52% |
| Dec 31, 2024 | 29.42% |
| Sep 30, 2024 | 40.48% |
| Jun 30, 2024 | 2.59% |
| Mar 31, 2024 | -2.53% |
| Dec 31, 2023 | 7.89% |
| Sep 30, 2023 | 23.39% |
| Jun 30, 2023 | 30.14% |
| Mar 31, 2023 | -48.86% |
| Dec 31, 2022 | 79.79% |
| Sep 30, 2022 | -83.53% |
| Jun 30, 2022 | -83.57% |
| Mar 31, 2022 | 8.12% |
| Dec 31, 2021 | 44.39% |
| Sep 30, 2021 | 176.09% |